Makiko Yamashita
Overview
Explore the profile of Makiko Yamashita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishihara H, Fukuda H, Mizoguchi Y, Yamashita M, Aoki K, Ishiyama R, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):51.
PMID: 39751827
Sex differences in the outcomes of advanced renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICIs) and the profiles of tumor-infiltrating immune cells (TIICs) remain unclear. We retrospectively evaluated...
2.
Yanai Y, Kosaka T, Mikami S, Arai M, Watanabe K, Takeda T, et al.
Prostate
. 2024 Nov;
85(3):308-314.
PMID: 39580660
Background: The influence of testosterone on the prostate's immune microenvironment remains unclear. This study aims to elucidate the dynamics of immune cells in the prostate following androgen deprivation therapy (ADT)....
3.
Maruyama S, Imamura Y, Toihata T, Haraguchi I, Takamatsu M, Yamashita M, et al.
Cancer Sci
. 2024 Oct;
116(1):178-191.
PMID: 39440906
The tumor immune microenvironment is increasingly becoming a key consideration in developing treatment regimens for aggressive cancers, with evidence that regulatory T cells (Tregs) attenuate the antitumor response by interrupting...
4.
Okamura K, Wang L, Nagayama S, Yamashita M, Tate T, Matsumoto S, et al.
Oncoimmunology
. 2024 Jul;
13(1):2373530.
PMID: 38979545
TCRαβ+ CD4- CD8- double-negative T (DNT) cells are minor populations in peripheral blood, and their roles have mostly been discussed in inflammation and autoimmunity. However, the functions of DNT cells...
5.
Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, et al.
Cancer Sci
. 2024 Mar;
115(6):1763-1777.
PMID: 38527308
Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non-small-cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal...
6.
Hanamura T, Yokoyama K, Kitano S, Kagamu H, Yamashita M, Terao M, et al.
Cancer Immunol Immunother
. 2024 Feb;
73(3):42.
PMID: 38349455
Background: Alpha-2-glycoprotein 1, zinc-binding (ZAG), a secreted protein encoded by the AZGP1 gene, is structurally similar to HLA class I. Despite its presumed immunological function, little is known about its...
7.
Hirose S, Mashima T, Yuan X, Yamashita M, Kitano S, Torii S, et al.
Cancer Sci
. 2024 Jan;
115(3):791-803.
PMID: 38258342
Cancer cells adopt multiple strategies to escape tumor surveillance by the host immune system and aberrant amino acid metabolism in the tumor microenvironment suppresses the immune system. Among the amino...
8.
Ikarashi D, Kitano S, Tsuyukubo T, Yamashita M, Matsuura T, Maekawa S, et al.
Sci Rep
. 2024 Jan;
14(1):1442.
PMID: 38228697
The prognosis for patients who achieve a pathologic complete response in bladder cancer is excellent, but the association between their prognosis and the tumor microenvironment is unclear. We investigated the...
9.
Aoki K, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, et al.
Cancer Res Commun
. 2023 Jun;
3(6):1026-1040.
PMID: 37377611
Significance: The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in...
10.
Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T, et al.
Breast Cancer Res
. 2023 Mar;
25(1):28.
PMID: 36941639
No abstract available.